These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38887198)

  • 1. Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti-SARS-CoV-2 Activity.
    Gege C; Hahn F; Wangen C; Häge S; Herrmann A; Uhlig N; Eberlein V; Issmail L; Klopfleisch R; Grunwald T; Marschall M; Kohlhof H; Vitt D
    ChemMedChem; 2024 Oct; 19(19):e202400292. PubMed ID: 38887198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
    Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses.
    Zheng Y; Li S; Song K; Ye J; Li W; Zhong Y; Feng Z; Liang S; Cai Z; Xu K
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors.
    Berber B; Doluca O
    Brief Bioinform; 2021 Mar; 22(2):1023-1037. PubMed ID: 33406218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines.
    Luban J; Sattler RA; Mühlberger E; Graci JD; Cao L; Weetall M; Trotta C; Colacino JM; Bavari S; Strambio-De-Castillia C; Suder EL; Wang Y; Soloveva V; Cintron-Lue K; Naryshkin NA; Pykett M; Welch EM; O'Keefe K; Kong R; Goodwin E; Jacobson A; Paessler S; Peltz SW
    Virus Res; 2021 Jan; 292():198246. PubMed ID: 33249060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
    Xiong R; Zhang L; Li S; Sun Y; Ding M; Wang Y; Zhao Y; Wu Y; Shang W; Jiang X; Shan J; Shen Z; Tong Y; Xu L; Chen Y; Liu Y; Zou G; Lavillete D; Zhao Z; Wang R; Zhu L; Xiao G; Lan K; Li H; Xu K
    Protein Cell; 2020 Oct; 11(10):723-739. PubMed ID: 32754890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.
    Demarest JF; Kienle M; Boytz R; Ayres M; Kim EJ; Patten JJ; Chung D; Gandhi V; Davey RA; Sykes DB; Shohdy N; Pottage JC; Kumar VS
    Antiviral Res; 2022 Oct; 206():105403. PubMed ID: 36041646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis.
    Marschall M; Niemann I; Kosulin K; Bootz A; Wagner S; Dobner T; Herz T; Kramer B; Leban J; Vitt D; Stamminger T; Hutterer C; Strobl S
    Antiviral Res; 2013 Dec; 100(3):640-8. PubMed ID: 24149002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
    Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
    Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
    Vyas VK; Ghate M
    Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity against Mammarenaviruses In Vitro.
    Kim YJ; Cubitt B; Cai Y; Kuhn JH; Vitt D; Kohlhof H; de la Torre JC
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32751087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH).
    Lucas-Hourani M; Munier-Lehmann H; El Mazouni F; Malmquist NA; Harpon J; Coutant EP; Guillou S; Helynck O; Noel A; Scherf A; Phillips MA; Tangy F; Vidalain PO; Janin YL
    J Med Chem; 2015 Jul; 58(14):5579-98. PubMed ID: 26079043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classical swine fever virus non-structural protein 4A recruits dihydroorotate dehydrogenase to facilitate viral replication.
    Zhao B-q; Chen J; Chen J-X; Cheng Y; Zhou J-f; Bai J-s; Mao D-y; Zhou B
    J Virol; 2024 Jun; 98(6):e0049424. PubMed ID: 38757985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication.
    Luganini A; Sibille G; Mognetti B; Sainas S; Pippione AC; Giorgis M; Boschi D; Lolli ML; Gribaudo G
    Antiviral Res; 2021 May; 189():105057. PubMed ID: 33716051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of isoquinolinone DHODH inhibitor isosteres.
    DeRatt LG; Zhang Z; Pietsch EC; Cisar J; Wang A; Wang CY; Tanner A; Shaffer P; Jacoby E; Kazmi F; Shukla N; Philippar U; Attar RM; Edwards JP; Kuduk SD
    Bioorg Med Chem Lett; 2024 Nov; 113():129965. PubMed ID: 39284456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Original 2-(3-alkoxy-1H-pyrazol-1-yl)pyrimidine derivatives as inhibitors of human dihydroorotate dehydrogenase (DHODH).
    Munier-Lehmann H; Lucas-Hourani M; Guillou S; Helynck O; Zanghi G; Noel A; Tangy F; Vidalain PO; Janin YL
    J Med Chem; 2015 Jan; 58(2):860-77. PubMed ID: 25558988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced virtual screening enables the discovery of a host-targeting and broad-spectrum antiviral agent.
    Chilingaryan G; Izmailyan R; Grigoryan R; Shavina A; Arabyan E; Khachatryan H; Abelyan N; Matevosyan M; Harutyunyan V; Manukyan G; Hietel B; Shtro A; Danilenko D; Zakaryan H
    Antiviral Res; 2023 Sep; 217():105681. PubMed ID: 37499699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.
    Zeng T; Zuo Z; Luo Y; Zhao Y; Yu Y; Chen Q
    FEBS Open Bio; 2019 Aug; 9(8):1348-1354. PubMed ID: 31087527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orally bioavailable RORγ/DHODH dual host-targeting small molecules with broad-spectrum antiviral activity.
    Herrmann A; Gege C; Wangen C; Wagner S; Kögler M; Cordsmeier A; Irrgang P; Ip WH; Weil T; Hunszinger V; Groß R; Heinen N; Pfaender S; Reuter S; Klopfleisch R; Uhlig N; Eberlein V; Issmail L; Grunwald T; Hietel B; Cynis H; Münch J; Sparrer KMJ; Ensser A; Tenbusch M; Dobner T; Vitt D; Kohlhof H; Hahn F
    Antiviral Res; 2024 Nov; 231():106008. PubMed ID: 39306285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus.
    Li J; Takeda M; Imahatakenaka M; Ikeda M
    J Med Virol; 2024 Jan; 96(1):e29372. PubMed ID: 38235544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.